Bionano Genomics (STU:2Y30) Cyclically Adjusted PB Ratio: (As of Aug. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2Y30 Bionano Genomics Inc STU:2Y30
43 GF Score
Price €315.84
GF Value €251.60
! 5 Warning Signs
View Full Analysis

What is Bionano Genomics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Bionano Genomics  (STU:2Y30) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Bionano Genomics Cyclically Adjusted PB Ratio Related Terms


Bionano Genomics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Bionano Genomics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionano Genomics Cyclically Adjusted PB Ratio Chart

Bionano Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bionano Genomics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:2Y30 vs RGNT, UEEC, FEMY: Cyclically Adjusted PB Ratio Comparison

For the Medical Instruments & Supplies subindustry, Bionano Genomics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bionano Genomics Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Bionano Genomics's Cyclically Adjusted PB Ratio falls into.


STU:2Y30
43GF Score
Bionano Genomics Inc STU:2Y30
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bionano Genomics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Bionano Genomics's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec25 is calculated as:

For example, Bionano Genomics's adjusted Book Value per Share data for the fiscal year that ended in Dec25 was:

Adj_Book=Book Value per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=3.532/324.0540*324.0540
=3.532

Current CPI (Dec25) = 324.0540.

Bionano Genomics Annual Data

Book Value per Share CPI Adj_Book
201612 -1,615.125 241.432 -2,167.847
201712 -2,652.625 246.524 -3,486.856
201812 524.118 251.233 676.036
201912 57.070 256.974 71.967
202012 90.968 260.474 113.173
202112 617.700 278.802 717.958
202212 475.620 296.797 519.300
202312 115.565 306.746 122.086
202412 18.114 315.605 18.599
202512 3.532 324.054 3.532

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Bionano Genomics (STU:2Y30) Overvalued in 2026?

Based on GuruFocus' analysis, Bionano Genomics stock appears to be overvalued. The current stock price of €315.84 is trading 25.5% above its estimated GF Value™ of €251.60.

Key valuation signals for STU:2Y30:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €251.60 vs. price of €315.84 (25.5% above fair value)
  • GF Score™: 43/100 with 5 warning signs

No single metric tells the full story. See the STU:2Y30 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bionano Genomics Business Description

Other Exchanges BNGO:USABNGO:Mexico
Address 9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
43GF Score

Get the complete analysis for STU:2Y30

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€315.84
Price
€251.60
GF Value